[Advances in the physiopathology of epileptogenesis: molecular aspects]
- PMID: 12040510
[Advances in the physiopathology of epileptogenesis: molecular aspects]
Abstract
Objective: We review the molecular basis of epileptogenesis and the new perspectives in the treatment of epilepsy.
Development: Epileptogenesis are the molecular and cellular events producing the disordered firing of a subpopulation of neurons resulting in periodic seizures. Epilepsies may be due to genetic and acquired factors. Some idiopathic epilepsies are due to mutant genes coding voltage gated sodium and potassium channels, GABAA receptor chloride channels and nicotinic acetylcholine receptor sodium channels. Genetic defects also produce epilepsy secondary to either neuronal developmental or metabolic abnormalities, and may contribute to acquired epilepsy. Events observed in both animal and human acquired epilepsies are an increase in glutamate levels and NMDA receptor sensitivity, selective lost of pyramidal neurons, mossy fibre sprouting and neosinaptogenesis. There is also a reduction in inhibitory control due to lost of GABAergic interneurons, and a decrease in GABA levels and GABAA receptor sensitivity. Hyperexcitability may be also due to reduction in glial ATPasa activity, increase in astrocytes gap junctions, and decrease in extracellular calcium. Chandelier GABAergic interneuron microlesions and an hyperexcitable thalamus are key in spread of partial seizures. Absences may be caused by cortex hyperexcitability and genetic abnormalities in thalamic voltage gated T calcium channels. Brain stem is key in convulsive seizures. The role of voltage gated potassium, sodium and calcium channels, and GABAergic and glutamatergic neurotransmission in epileptogenesis and treatment of epilepsies are revised. The role of other neurotransmitters and neuromodulators, second messengers, and immediate early genes and neurotrophins are also commented.
Conclusion: Understanding the molecular basis of epileptogenesis should lead to the rational design of drugs both to prevent the development of epilepsy, and minimize hyperexcitability which may be the result of a genetic or acquired disorder.
Similar articles
-
[Ion channels and epilepsy].Rev Neurol. 2000 Jun;30 Suppl 1:S25-41. Rev Neurol. 2000. PMID: 10904966 Review. Spanish.
-
Basic developmental rules and their implications for epilepsy in the immature brain.Epileptic Disord. 2006 Jun;8(2):91-102. Epileptic Disord. 2006. PMID: 16793570 Review.
-
Pathophysiology of epilepsy.Acta Neurol Belg. 2000 Dec;100(4):201-13. Acta Neurol Belg. 2000. PMID: 11233674 Review.
-
Glutamate alteration of glutamic acid decarboxylase (GAD) in GABAergic neurons: the role of cysteine proteases.Exp Neurol. 2008 Sep;213(1):145-53. doi: 10.1016/j.expneurol.2008.05.013. Epub 2008 May 27. Exp Neurol. 2008. PMID: 18599042
-
[The neurochemical mechanisms of temporal lobe epilepsy: an update].Przegl Lek. 2007;64(11):960-4. Przegl Lek. 2007. PMID: 18409413 Review. Polish.
Cited by
-
Transcriptome Derived Artificial neural networks predict PRRC2A as a potent biomarker for epilepsy.J Genet Eng Biotechnol. 2025 Jun;23(2):100503. doi: 10.1016/j.jgeb.2025.100503. Epub 2025 May 12. J Genet Eng Biotechnol. 2025. PMID: 40390496 Free PMC article.
-
SOX6 controls dorsal progenitor identity and interneuron diversity during neocortical development.Nat Neurosci. 2009 Oct;12(10):1238-47. doi: 10.1038/nn.2387. Epub 2009 Aug 5. Nat Neurosci. 2009. PMID: 19657336 Free PMC article.
-
Benzodiazepine partially reverses tonic-clonic seizures induced by thiocolchicoside.Braz J Med Biol Res. 2022 Feb 28;55:e11771. doi: 10.1590/1414-431X2021e11771. eCollection 2022. Braz J Med Biol Res. 2022. PMID: 35239777 Free PMC article.
-
Caspase 3 involves in neuroplasticity, microglial activation and neurogenesis in the mice hippocampus after intracerebral injection of kainic acid.J Biomed Sci. 2013 Dec 6;20(1):90. doi: 10.1186/1423-0127-20-90. J Biomed Sci. 2013. PMID: 24313976 Free PMC article.
-
Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.Neuromolecular Med. 2003;3(2):65-94. doi: 10.1385/NMM:3:2:65. Neuromolecular Med. 2003. PMID: 12728191 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous